Linperlisib is under clinical development by Shanghai Yingli Pharmaceutical and currently in Phase II for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia). According to GlobalData, Phase II drugs for T-Cell Acute Lymphocytic Leukemia (T-Cell Acute Lymphoblastic Leukaemia) have a 20% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Linperlisib’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Linperlisib overview
Linperlisib (Intarel) is an antineoplastic agent. It is formulated as a tablet for the oral route of administration. Intarel is indicated for the treatment of adult patients with relapsed and refractory follicular lymphoma who have received at least two systemic treatments in the past.
YY-20394 is under development for the treatment of recurrent or refractory peripheral t-cell lymphoma, relapsed and refractory diffuse large B-cell lymphoma, unspecified T-cell lymphomas, peripheral T-cell lymphoma, angioimmunoblastic T-cell lymphoma, ALK-positive and negative resistance large cell lymphoma, mantle cell lymphoma, B-cell non-Hodgkin lymphoma, subcutaneous panniculitis-like T-cell lymphoma, and other PTCL subtypes, follicular lymphoma, chronic lymphocytic leukemia or small lymphocytic lymphoma, solid tumors and B-cell hematological malignancies, nasopharyngeal Cancer, head and neck cancer, non-small cell lung cancer (NSCLC), small cell lung cancer, gallbladder cancer, cholangiocarcinoma, pancreatic cancer, urothelial carcinoma, renal cell carcinoma cancer, ovarian cancer, endometrial cancer, and relapsed/refractory large granular t lymphocytic leukemia. The drug candidate is administered orally. It acts by targeting PI3 kinase delta.
It was under development for the treatment of relapsed/refractory thymic cancer, relapsed / refractory autoimmune hemolytic anemia.
Shanghai Yingli Pharmaceutical overview
Shanghai Yingli Pharmaceutical (Yingli) is a pharmaceutical company focused on discovery and development of innovative small molecule drugs for the treatment of cancer, autoimmune diseases, and metabolic disorders. Yingli is headquartered in Shanghai, China.
For a complete picture of Linperlisib’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
